REDDIE Partners at EASD Annual Meeting 2024
From September 9th to 13th, the 60th European Association for the Study of Diabetes (EASD) Annual Meeting will bring together the brightest minds in...
Randomised controlled trials (RCT) are the cornerstone of evidence-based medicine. However, the digitisation of real-world data (RWD) including data from devices, wearables, and electronic health records in large national registries provides opportunities to demonstrate efficacy and safety of innovative technologies including drugs, devices, diagnostics, and digital health. These data are particularly relevant to long-term conditions such as diabetes mellitus, where drugs, lifestyle interventions, and digital technologies often work together.
“In REDDIE, we will first define a typical target parameter of an RCT and then look for all people exposed to the same intervention in four comprehensive European real-world databases (Sweden, Denmark, Germany and England).
In this way, we ‘recreate’ the RCT trial within the real-world databases. Due to the large amount of real-world data we have available, we will get much faster answers to our research questions, tested in a much bigger cohort than this would ever be possible with RCTs.”
Dr Julia Mader, Medical University of Graz, REDDIE coordinator